Home › Pulmonary Hypertension › NCT06351345
129 Xenon Imaging in Patients Treated With Sotatercept
RecruitingPhase 2
129Xenon MR Imaging and Spectroscopy Response to Sotatercept in Pulmonary Arterial Hypertension
Who can join
Ages 18 to 75 · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Outpatients of either gender, Age 18-75 2. Diagnosis of precapillary PH (right heart catheterization demonstrating hemodynamic criteria of a mean pulmonary artery pressure (mPAP) ≥ 20 mmHg, pulmonary vascular resistance ≥ 5 WU, pulmonary capillary wedge pressure ≤ 15 mmHg) in the setting of Group 1 (PAH) 3. Willing and giving informed consent and adhere to visit/protocol schedules (consent must be given before any study procedures are performed). 4. On a stable dose of background PAH therapy for \> 90 days prior to study enrollment 5. Women of childbearing potential must have a negative urine pregnancy test before MRI Exclusion Criteria: 1. Moderate to severe heart disease (LVEF \< 45%, Severe LV hypertrophy, Moderate to severe valvular disease) 2. Chronic thromboembolic disease 3. PH due to schistosomiasis 4. Active cancer 5. Sickle cell anemia 6. Prisoners and pregnant women will not be approached for the study 7. Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to lie supine) 8. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the participant or interfere with the participant's ability to comply with the protocol requirements
About the study
Determine the ability of 129Xe MRI/MRS biomarker signatures to non-invasively monitor pulmonary vascular reverse remodeling induced by sotatercept in pulmonary arterial hypertension (PAH).
What is being tested
- 129Xe Hyperpolarized (drug)
Sponsor: Bastiaan Driehuys · Participants: 14 · Started: Oct 27, 2025
Contact the study team
- Claudia Salazar · Phone: +1 919 660 2026
Official record on ClinicalTrials.gov — NCT06351345
Locations in the U.S.
| North Carolina | Duke University Medical Center, Durham |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.